Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.

Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.
复制标题

DOI:
10.3389/fimmu.2021.688460
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Bertaina A
Bertaina A
中科院分区:
医学2区
文献类型:
--
作者:
Slepicka PF;Yazdanifar M;Bertaina A

文献摘要

参考文献

相似文献

实体器官移植(SOT)后的生存受到慢性排斥反应以及需要终生免疫抑制及其相关毒性的限制。几项临床前和临床研究已经测试了旨在诱导移植耐受而无需终生免疫抑制的方法。这些策略的有限成功导致了将 SOT 与其他方法(例如同种异体造血干细胞移植 (HSCT))相结合的临床方案的开发。 SOT 之前的 HSCT 有助于供体细胞的植入,从而提高免疫耐受性。移植物操作策略和 HSCT 后免疫治疗的最新创新在促进耐受性和改善临床结果方面提供了进一步的进展。在这篇综述中,我们讨论了 SOT 接受者免疫耐受发展背后的传统和非常规免疫机制,以及它们如何为临床进展提供信息。具体来说,我们回顾了最新的机制研究,阐明哪些免疫调节细胞抑制细胞毒性免疫反应,同时培育耐受环境。我们进一步讨论了对调节细胞的理解如何塑造移植工程和其他治疗策略,以改善接受 HSCT 和 SOT 的患者的长期结果。
Survival after solid organ transplantation (SOT) is limited by chronic rejection as well as the need for lifelong immunosuppression and its associated toxicities. Several preclinical and clinical studies have tested methods designed to induce transplantation tolerance without lifelong immune suppression. The limited success of these strategies has led to the development of clinical protocols that combine SOT with other approaches, such as allogeneic hematopoietic stem cell transplantation (HSCT). HSCT prior to SOT facilitates engraftment of donor cells that can drive immune tolerance. Recent innovations in graft manipulation strategies and post-HSCT immune therapy provide further advances in promoting tolerance and improving clinical outcomes. In this review, we discuss conventional and unconventional immunological mechanisms underlying the development of immune tolerance in SOT recipients and how they can inform clinical advances. Specifically, we review the most recent mechanistic studies elucidating which immune regulatory cells dampen cytotoxic immune reactivity while fostering a tolerogenic environment. We further discuss how this understanding of regulatory cells can shape graft engineering and other therapeutic strategies to improve long-term outcomes for patients receiving HSCT and SOT.
DOI: 10.1126/scitranslmed.3008793
发表时间: 2014-06-25
影响因子: 17.1
作者:
Bohne, Felix;Londono, Maria-Carlota;Sanchez-Fueyo, Alberto
通讯作者: Sanchez-Fueyo, Alberto
DOI: 10.1126/science.285.5428.727
发表时间: 1999-07-30
期刊: SCIENCE
影响因子: 56.9
作者:
Bauer, S;Groh, V;Spies, T
通讯作者: Spies, T
DOI: 10.1080/2162402x.2016.1216291
发表时间: 2017-01-01
期刊: ONCOIMMUNOLOGY
影响因子: 7.2
作者:
Bertaina, A.;Zorzoli, A.;Airoldi, I.
通讯作者: Airoldi, I.
DOI: 10.1182/blood-2018-07-861575
发表时间: 2018-12-13
期刊: BLOOD
影响因子: 20.3
作者:
Bertaina, Alice;Zecca, Marco;Locatelli, Franco
通讯作者: Locatelli, Franco
DOI: 10.4049/jimmunol.0803404
发表时间: 2009-02-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Bamboat ZM;Stableford JA;Plitas G;Burt BM;Nguyen HM;Welles AP;Gonen M;Young JW;DeMatteo RP
通讯作者: DeMatteo RP